Document is current
Any future updates will be listed below
-
Authors
Perucca, Alice https://orcid.org/0000-0003-1602-0199
Llonín, Andrea Gómez
Benach, Oriol Mañé
Hallopeau, Clement https://orcid.org/0000-0002-0692-2407
Rivas, Elisa I.
Linares, Jenniffer
Garrido, Marta
Sallent-Aragay, Anna
Golde, Tom https://orcid.org/0000-0002-3288-5646
Colombelli, Julien https://orcid.org/0000-0002-2784-4276
Dalaka, Eleni https://orcid.org/0000-0003-3306-7466
Linacero, Judith
Cazorla, Marina
Galan, Teresa
Pastor Viel, Jordi
Badenas, Xavier
Recort-Bascuas, Alba
Comerma, Laura https://orcid.org/0000-0002-0249-4636
Fernandez-Nogueira, Patricia
Rovira, Ana https://orcid.org/0000-0003-1301-2599
Roca-Cusachs, Pere https://orcid.org/0000-0001-6947-961X
Albanell, Joan
Trepat, Xavier https://orcid.org/0000-0002-7621-5214
Calon, Alexandre https://orcid.org/0000-0002-3398-6131
Labernadie, Anna https://orcid.org/0000-0001-5768-5088
- License Information
-
More Information
Article History
Received: 26 January 2023
Accepted: 13 January 2025
First Online: 3 February 2025
Competing interests
: J.A. has received consulting fees and honoraria from Seagen, Pfizer, AstraZeneca, Lilly, Merck, Roche, Gilead, Novartis and Daiichi-Sankyo, receives royalties from a licensed patent to Biocartis (EP11382270.4; Mutations in the epidermal growth factor receptor gene) and holds stock options from Inbiomotion. L.C. reports receiving personal fees from Roche, MSD, AstraZeneca and Diaceutics, non-financial support from Roche, MSD, AstraZeneca and Phillips and held advisory roles for Roche and AstraZeneca. Other authors declare no competing interests.
